Mylan.
former pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 133
What's happening
Earlier this month
One to three months ago
-
Boundless Bio merges with Serapha Bio, while McKesson, Viatris, and C.H. Robinson announce major acquisitions.Some support1 report
-
Viatris announced a plan to acquire Pacira Biosciences, expanding its portfolio to include Exparel.Well supported6 reports
-
Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.Some support4 reports1 development inside
-
Zymeworks is leveraging Irish tax attributes as part of its deal with Mylan.Some support1 report
-
The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.Some support4 reports
-
Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.Some support1 report
Gone quiet
No new reports in 90+ days-
Pharmac made Mylan patches easier to access, a development that Martin subsequently discussed.Some support3 reports
-
Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.Some support1 report
-
Acquisition of TYRVAYA nasal spray from Viatris.Some support1 report
-
Mylan, a company, is headquartered in Canonsburg, PA, and its stock performance is benchmarked against the S&P 500.Some support1 report
-
Mylan faces annual sales erosion in developed markets, specifically North America and Europe.Some support1 report
-
Mylan plans to sell up to 92 million shares in Biocon.Some support1 report
-
The Protagonist worked at Viatris/Mylan for 33 years.Some support1 report
-
Mizuho Bank led lenders providing a loan to Viatris, which is headquartered in Pennsylvania and listed on Nasdaq.Some support1 report
-
IgAN is developing a targeted-release budesonide therapy, with an NDA submission targeted for the end of 2026.Some support1 report
-
Mylan reached an exclusive multi-year commercial agreement with Shield Therapeutics plc for the U.S. launch of a product.Well supported4 reports
-
Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.Some support1 report1 development inside
-
Church & Dwight, Eli Lilly, and Viatris were all featured in Zacks Investment Ideas on September 4, 2025.Some support2 reports
-
China approval on 2025-07-15 triggers a payment owed to Theravance Biopharma.Some support1 report
-
Viatris achieved Great Place To Work certification and established a presence in Canada, led by Jeffrey Long.Some support1 report
-
Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.Some support2 reports
-
Viatris, headquartered in Canonsburg, Pennsylvania, lagged behind the S&P 500 Index and the Health Care Select Sector SPDR Fund on July 23, 2025.Some support1 report
-
Viatris and Microsoft were mentioned together as examples of diverse winners in thematic investing.Some support1 report
-
Michael Goettler, formerly of Viatris, was appointed to the Board of Directors of Bausch Health.Some support4 reports
-
Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.Some support2 reports
-
Viatris executives, including CFO Doretta Mistras and CEO Scott Smith, provided corporate guidance expectations and noted positive Phase III readouts on August 13, 2025.Some support1 report
-
Major pharmaceutical companies, including Johnson & Johnson, GlaxoSmithKline, and Viatris, are key players in the Paracetamol Market.Some support1 report
-
Viatris faced sales impacts due to government-driven price regulations and facility inspections at its Indore facility, affecting markets including Europe and North America.Some support1 report
-
Viatris is managing ongoing dialogues with the FDA, addressing investor queries regarding share repurchases, and reporting on operational growth in Europe and China.Some support3 reports1 development inside
-
Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production.Well supported4 reports1 development inside
-
Viatris was classified into the Zacks Medical Services industry as of August 7, 2025.Some support1 report
-
Viatris is involved in a development where Australia, New Zealand, and Japan are part of the JANZ segment.Some support1 report1 development inside
-
A market rally occurred on August 13, 2025, driven by positive inflation data, involving Viatris, Bruker, Sotera Health Company, Align Technology, and Omnicell.Some support1 report
-
Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.Some support1 report
-
Viatris appointed Andrew Enrietti to a new role in August 2025.Some support1 report
-
FDA approved Iron Sucrose Injection for Viatris on August 12, 2025.Some support2 reports
-
Viatris gained China approval for the commercialization of Yupelri.Speculative1 report
-
Mylan merged with Pfizer's Upjohn division, which was part of Viatris, leading to volatility in the stocks of the involved companies.Well supported14 reports
-
Viatris stock significantly underperformed SPX and peer Sanofi on June 24, 2025.Some support2 reports
-
Philippe Martin was appointed Chief R&D Officer at Viatris in June 2025.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Mylan this week
News at the entities that move Mylan most-
FDA StructuralIndian products were subject to an FDA recall.Moves Mylan
-
Pfizer StructuralICICI Prudential Mutual Fund's portfolio includes top picks such as Bajaj Finserv, HDFC Bank, and Pfizer.Moves Mylan
-
U.S. Treasury Mentioned togetherThe Office of the Comptroller of the Currency and U.S. Treasury fined Bank of America for reporting and compliance failures.Moves Mylan
-
board of directors StructuralGagne was appointed to represent Franklin County on the VMSMA Board.Moves Mylan
-
North America Shared contextMicrosoft experienced a service outage affecting Outlook and other Microsoft 365 products across Europe and North America.Moves Mylan
Connections
The 30 strongest of 133, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Upjohn Structural
The relationship is structural, established by the 2020 merger of Upjohn division into Mylan.
-
Pfizer Structural
Mylan was absorbed into the corporate structure stemming from Pfizer's Upjohn division, leading to the formation of Viatris.
-
FDA Structural
FDA formally regulates Mylan's pharmaceutical products through inspections, protocols, and granting approvals.
-
Teva Pharmaceutical Industries Ltd. Operational
Teva and Mylan are direct competitors in the generic drug market and have been implicated in anti-competitive practices regarding generic release timelines.
-
Biocon Transactional
Mylan is currently planning the divestment of its 5.64% equity stake in Biocon.
-
board of directors Structural
The Board of Directors governs Mylan, as evidenced by the declaration of a quarterly dividend.
-
Heron Operational
Heron and Mylan actively compete in the generic drug market and engage in licensing agreements.
-
Barclays Mentioned together
Barclays provides financial analysis and price targets regarding Mylan's (Viatris) quarterly results.
Show all 30 connections
-
Zymeworks Operational
The evidence suggests a functional partnership where Zymeworks leverages market access provided by the entity currently operating under the Viatris umbrella, which is the operational successor to Mylan.
-
SPX Mentioned together
Mylan's stock performance is frequently benchmarked against the gains of the S&P 500 index.
-
Martin Mentioned together
Martin is cited as an expert discussing Mylan's patch accessibility issues.
-
TD SYNNEX Shared context
Both companies are discussed in the context of small-cap value stocks targeted by ETFs.
-
Japan Shared context
Mylan's sales and market approval processes are governed by Japanese government regulations and reimbursement policies.
-
Europe Shared context
Mylan's sales and performance are observed within the European market context.
-
U.S. Treasury Mentioned together
U.S. Treasury yield is used as a financial benchmark to evaluate the earnings yield of companies like Mylan.
-
Canonsburg Shared context
The company operates from its headquarters in Canonsburg.
-
Concord Biotech Transactional
Concord Biotech acquired a company from Mylan in a historical transaction.
-
Shanghai Shared context
Mylan maintains global operational centers within Shanghai.
-
North America Shared context
Mylan operates within the North American market, which is characterized by annual sales erosion in developed markets.
-
Hyderabad Shared context
The company maintains global centers within the city of Hyderabad.
-
American College of Cardiology Mentioned together
Both companies are mentioned as generic companies benefiting from the current regulatory climate.
-
Harrow Borough F.C. Mentioned together
The provided evidence does not contain information linking Harrow Borough F.C. and Mylan.
-
Pennsylvania Shared context
Mylan's successor company, Viatris, is headquartered in Pennsylvania.
-
Nasdaq Shared context
Mylan is a company listed on the Nasdaq stock exchange.
-
UAE Shared context
Mylan (Viatris) is strategically planning to build a long-term presence and expand into the regional markets of the UAE.
-
Pittsburgh Shared context
Viatris, Mylan's successor, maintains a global center and headquarters in Pittsburgh.
-
Church of the Brethren Mentioned together
No evidence of a relationship between Church of the Brethren and Mylan was found in the provided timeline.
-
foundation Transactional
The relationship was observed through a specific instance where Viatris contributed as a major sponsor.
-
Mizuho Bank Mentioned together
No evidence was provided linking Mizuho Bank and Mylan.
-
Martin Mentioned together
No direct relationship between Martin and Mylan was observed in the provided evidence timeline.
History
Events by the month they beganNovember 2026
1 eventOctober 2026
2 eventsSeptember 2026
2 eventsShow 3 earlier months
August 2026
4 events- Pharmac made Mylan patches easier to access, a development that Martin subsequently discussed.
- Barclays raised its price target on Viatris to US$22, citing the company's strong Q1 results.
- Acquisition of TYRVAYA nasal spray from Viatris.
- Mylan, a company, is headquartered in Canonsburg, PA, and its stock performance is benchmarked against the S&P 500.
July 2026
5 events- Mylan faces annual sales erosion in developed markets, specifically North America and Europe.
- Mylan plans to sell up to 92 million shares in Biocon.
- The Protagonist worked at Viatris/Mylan for 33 years.
- Mizuho Bank led lenders providing a loan to Viatris, which is headquartered in Pennsylvania and listed on Nasdaq.
- IgAN is developing a targeted-release budesonide therapy, with an NDA submission targeted for the end of 2026.
June 2026
28 events- Viatris is headquartered in the U.S. and maintains global operational centers in Pittsburgh, Shanghai, and Hyderabad.
- Mylan and Zymeworks are involved in a deal aimed at bolstering Zymeworks’ commercial portfolio, related to COPD therapy.
- The new event concerns the impact of Trump-era tariffs and onshoring trends on Viatris.
- Mylan reached an exclusive multi-year commercial agreement with Shield Therapeutics plc for the U.S. launch of a product.
- Janssen Pharmaceuticals, Gilead Sciences, Emcure Pharmaceuticals, and Mylan are key players in the Lenacapavir Injection Market.
- Church & Dwight, Eli Lilly, and Viatris were all featured in Zacks Investment Ideas on September 4, 2025.
- China approval on 2025-07-15 triggers a payment owed to Theravance Biopharma.
- Viatris achieved Great Place To Work certification and established a presence in Canada, led by Jeffrey Long.
- Novo Nordisk became the licensee for Lexicon's LX9851, and Viatris filed to bring sotagliflozin to markets.
- Viatris, headquartered in Canonsburg, Pennsylvania, lagged behind the S&P 500 Index and the Health Care Select Sector SPDR Fund on July 23, 2025.
- Viatris and Microsoft were mentioned together as examples of diverse winners in thematic investing.
- Michael Goettler, formerly of Viatris, was appointed to the Board of Directors of Bausch Health.
- Viatris recognized Yupelri net sales, and Theravance sold TRELEGY royalty interest to GSK.
- Viatris executives, including CFO Doretta Mistras and CEO Scott Smith, provided corporate guidance expectations and noted positive Phase III readouts on August 13, 2025.
- Major pharmaceutical companies, including Johnson & Johnson, GlaxoSmithKline, and Viatris, are key players in the Paracetamol Market.
- Viatris faced sales impacts due to government-driven price regulations and facility inspections at its Indore facility, affecting markets including Europe and North America.
- Viatris is managing ongoing dialogues with the FDA, addressing investor queries regarding share repurchases, and reporting on operational growth in Europe and China.
- Philippe Martin was named Viatris' chief R&D officer, while Novartis and Teva are noted for drug approvals and generic production.
- Viatris was classified into the Zacks Medical Services industry as of August 7, 2025.
- Viatris is involved in a development where Australia, New Zealand, and Japan are part of the JANZ segment.
- A market rally occurred on August 13, 2025, driven by positive inflation data, involving Viatris, Bruker, Sotera Health Company, Align Technology, and Omnicell.
- Viatris and Theravance are collaborating on product sales involving Yupelri, with Viatris recording product sales on August 14, 2025.
- Viatris appointed Andrew Enrietti to a new role in August 2025.
- FDA approved Iron Sucrose Injection for Viatris on August 12, 2025.
- Viatris gained China approval for the commercialization of Yupelri.
- Mylan merged with Pfizer's Upjohn division, which was part of Viatris, leading to volatility in the stocks of the involved companies.
- Viatris stock significantly underperformed SPX and peer Sanofi on June 24, 2025.
- Philippe Martin was appointed Chief R&D Officer at Viatris in June 2025.